Does cimzia treat as?

See the DrugPatentWatch profile for cimzia

What conditions does Cimzia treat?

Cimzia (certolizumab pegol) is a biologics medication that treats several chronic inflammatory conditions. According to the FDA [1], Cimzia is approved to treat:

* Moderate to severe rheumatoid arthritis in adults, in combination with methotrexate
* Moderate to severe psoriatic arthritis in adults, in combination with methotrexate
* Moderate to severe Crohn's disease in adults, including those who have previously failed treatment with other medications

How does Cimzia work?

Cimzia belongs to a class of medications known as tumor necrosis factor-alpha inhibitors (TNF-alpha inhibitors). These medications work by blocking the action of a protein called tumor necrosis factor-alpha (TNF-alpha), which is involved in the inflammatory process. By blocking TNF-alpha, Cimzia reduces inflammation and symptoms in patients with the above-mentioned conditions [2].

Similar medications:

Cimzia is often compared with other TNF-alpha inhibitors, such as etanercept (sold under the brand name Enbrel), adalimumab (sold under the brand name Humira), and infliximab (sold under the brand name Remicade) [3]. While all of these medications work in a similar way, they may have slightly different side effect profiles and dosing regimens.

Patent information:

Cimzia's patent for the treatment of rheumatoid arthritis expires on May 27, 2021 [4]. However, this may not impact the medication's availability in pharmacies, as patent expirations often lead to the introduction of generic or biosimilar versions.

Sources:

[1] FDA. (2022). Cimzia (certolizumab pegol) prescribing information.

[2] Biogen. (n.d.). Cimzia (certolizumab pegol) - Mechanism of Action.

[3] National Institutes of Health. (n.d.). Cimzia (certolizumab pegol).

[4] DrugPatentWatch.com. (n.d.). Certolizumab pegol (Cimzia) patent expiration dates.